Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial

Aug. 02, 2022 9:29 AM ETContext Therapeutics Inc. (CNTX)By: Anuron Mitra, SA News Editor

Love, Health Care, Donation and Charity Concept. Breast Cancer Awareness. World Cancer Survivor Day

BlackSalmon

  • Context Therapeutics (NASDAQ:CNTX) and Italian pharmaceutical major Menarini Group have entered into a clinical trial collaboration and supply agreement to evaluate a breast cancer combination treatment, the companies said on Tuesday.
  • The agreement will support the upcoming phase 1b/2 ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor.
  • Context (CNTX) will sponsor the trial while Menarini will supply elacestrant at no cost.
  • CNTX said it anticipates starting the phase 1b/2 trial in Q4 this year.
  • CNTX stock gained 5.8% to $2 in premarket trading.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.